SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors react to the company's AI robotics spinoff and look ahead to its Autonomy Day in December. Bulls are hopeful, citing potential short squeezes and progress on the R2 vehicle, while bears remain skeptical about long-term profitability and upcoming earnings. The community is actively debating the company's prospects and the impact of recent developments.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as investors anticipate the company's earnings report, with community members discussing potential outcomes and price movements. Bullish sentiment seems to be fueled by the expectation of strong numbers, particularly from the company's expansion into prediction markets. Some traders are also eyeing Robinhood's potential partnership with OpenDoor, while others are concerned about the impact of overall market conditions on the stock's performance post-earnings.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community members discuss its ongoing bidding war with Pfizer for Metsera, a company with promising obesity drug candidates, and whether NVO is overpaying. Additionally, details surrounding a potential deal with the White House to lower drug prices are circulating, sparking debate about its impact. Some traders are looking to Lilly's performance as a bellwether.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

APPS is trending as investors discuss its technical bull trend and anticipation of double-digit stock value by 2026, fueled by a recent earnings beat and higher guidance; however, some community members are pointing to a potential round-trip, pump and dump pattern following earnings, creating a volatile trading environment, while others are anticipating positive growth after the recent news.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

ENVB is trending due to speculation of a potential short squeeze, fueled by its low float and comparisons to previous meme stock runners like BYND and HTZ. The community is actively discussing its potential to break through resistance levels and reach higher prices, with some mentioning YouTube videos and Reddit attention as contributing factors. Some investors believe a patent payout may be coming as well.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul C. Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Despite strong revenue growth driven by AI-powered ad tools and a surge in MAUs, PINS is trending due to concerns about missed earnings and soft Q4 guidance, leading to community frustration and a significant stock drop. Investors are debating whether the company's growth potential outweighs the earnings miss, while also watching for potential catalysts such as partnerships or a possible acquisition.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is trending as the stock experiences a significant surge, driven by raised Q4 guidance, leading to speculation of a potential short squeeze. Community discussions revolve around whether this rally is sustainable, with some pointing to high short interest and others suggesting the price is overvalued.  Additionally, some investors are drawing comparisons to related companies like $ROOT.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending as investors debate its potential ahead of earnings, with community sentiment split between bullish expectations of a breakout driven by new partnerships and subscriber growth, and bearish concerns over continued losses and disappointing guidance. Discussions also include potential acquisitions and the impact of the company's AR strategy. Technical analysis and options activity are being closely watched for signals.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending as the community discusses its partnership with OpenAI and potential integrations with ChatGPT, driving bullish sentiment and speculation about a short squeeze. Some traders see the recent price action as a breakout opportunity, while others remain cautious, pointing to valuation concerns and competition from established players like Adobe. Overall, the focus is on whether this AI integration can significantly impact Figma's growth trajectory and market position.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is trending following a surprising earnings beat, leading to discussions of a potential short squeeze reminiscent of meme stock rallies. Community members are actively debating whether the company's improving financials and high short interest could fuel further gains. Some are drawing comparisons to other stocks that experienced massive short squeezes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Equity

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.


Nasdaq-listed shares of UK-based TC BioPharm (Holdings) PLC (TCBP) tumbled 64% by Friday afternoon after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tcbp-announces-transition-from-nasdaq-to-otc-markets-302408102.html">said</a> its securities would be delisted from the exchange.The delisting follows the company’s failure to maintain a minimum bid price of $1 per share. The company said that its management is working on an appeal with Nasdaq and expressed optimism that its American Depositary Shares will be eligible to trade on the OTC markets starting Monday.Earlier this week, the company announced a reduction in its workforce and other measures aimed at reducing core operational burn by 55% compared to last year. The layoff impacted approximately 20 employees, or <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tcbiopharm.com/news/press-releases/detail/122/tcbp-announces-outsourcing-initiatives-reducing-burn-rate">half of the company’s total headcount</a>.On Stocktwits, investors expressed frustration over the news.&nbsp;<stembedurl>https://stocktwits.com/Blackdog111/message/608838652</stembedurl>One user opined that there is little chance for recovery for the company’s stock.<stembedurl>https://stocktwits.com/Oxinternet/message/608832026</stembedurl>In early March, TC BioPharm announced that it had executed a non-binding letter of intent to acquire 100% of a commercial-stage ophthalmic pharmaceutical company in an all-stock transaction.CEO Bryan Kobel said the firm expects to execute the binding letter of intent in a few weeks and close the acquisition around the third quarter of this year.At the beginning of 2025, Kobel <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tcbp-issues-25-stock-dividend-302340235.html">said</a> he anticipated 2025 to be a “period of growth and development” for the company. He expressed “strong confidence” in the company’s financial future after issuing a special dividend of 0.25 &nbsp;American Depositary Shares (ADSs) for every ADS held by shareholders.&nbsp;The stock has dropped by over 94% this year, wiping nearly all its value over the past twelve months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rio-tinto-eyes-bigger-us-footprint-amid-copper-price-surge-fueled-by-trump-tariffs/ch7oTeGRb53">Rio Tinto Reportedly Eyes Bigger US Footprint Amid Copper Price Surge Fueled By Trump Tariffs – Stock Drops, Retail Sentiment Weakens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

TC BioPharm Stock Crashes On Nasdaq Delisting: Retail Expresses Frustration

The company said that its management is working on an appeal with Nasdaq and expressed optimism that its American Depositary Shares will be eligible to trade on the OTC markets starting Monday.

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life...

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial PR Newswire EDINBURGH, Scotland, Feb. 13...

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical...

TCBP to Implement ADS Ratio Change

TCBP to Implement ADS Ratio Change TCBP to Implement ADS Ratio Change PR Newswire EDINBURGH, Scotland, Feb. 5, 2025 EDINBURGH, Scotland, Feb. 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ('TC...

TCBP Announces H5N1 Proof of Concept Studies Intention

TCBP Announces H5N1 Proof of Concept Studies Intention TCBP Announces H5N1 Proof of Concept Studies Intention PR Newswire EDINBURGH, Scotland, Jan. 15, 2025 EDINBURGH, Scotland, Jan. 15, 2025...

TCBP to Present at Sequire Investor Summit 2025

TCBP to Present at Sequire Investor Summit 2025 TCBP to Present at Sequire Investor Summit 2025 PR Newswire EDINBURGH, Scotland, Jan. 13, 2025 EDINBURGH, Scotland, Jan. 13, 2025 /PRNewswire/ -- TC...

TCBP Trading Continues Unabated on Nasdaq Stock Exchange

TCBP Trading Continues Unabated on Nasdaq Stock Exchange TCBP Trading Continues Unabated on Nasdaq Stock Exchange PR Newswire EDINBURGH, Scotland, Jan. 6, 2025 EDINBURGH, Scotland, Jan. 6, 2025...

TCBP Provides Update on Acquisition Strategy and Current Targets

TCBP Provides Update on Acquisition Strategy and Current Targets TCBP Provides Update on Acquisition Strategy and Current Targets PR Newswire EDINBURGH, Scotland, Dec. 31, 2024 EDINBURGH, Scotland...

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

TC BioPharm (Holdings) plc - ADR

$HOOD

$APP

$FIG

$SNAP

Which earnings release are you most excited for after the close?  
 
Drop a comment for others.

TCBP
TC BioPharm Holdings Ltd

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest TCBP News

TCBPTC BioPharm Holdings Ltd